Abstract: The invention include glycopeptides having a glycoside and a peptide covalently bound through an amide bond. The glycopeptides may also include a diagnostic or therapeutic agent bound to the glycopeptide. A metal, such as a radionuclide, may also be chelated to the glycopeptide. Specific embodiments of the invention relate to glycopeptides made of chitosan covalently bound to a poly(amino acid) such as poly(glutamic acid) or poly(aspartic acid). Diagnostic agents conjugated to the glycopeptide may facilitate imaging. Specific therapeutic agents that may be conjugated to the glycopeptide include anticancer drugs, rheumatoid arthritis drugs, anticoagulants, anti-angiogenesis drugs, apoptosis drugs, osteoporosis drugs, steroids, and anti-inflammatory drugs. Some agents, such as radionuclides, may have both diagnostic and therapeutic effects.

Abstract: A method of synthesizing a polysaccharide conjugate used for cancer therapy is provided. The method comprises the following steps. A polysaccharide having at least one reactive functional group is provided. The polysaccharide is reacted with at least one monomeric amino acid having an O-group, such that the at least one monomeric amino acid is covalently bound to the polysaccharide by reacting with the reactive functional group to form an amide bond. At least one metal is conjugated to the at least one monomeric amino acid through the O-group so as to form the polysaccharide conjugate. Furthermore, a method for cancer therapy that uses the polysaccharide conjugate obtained by the method above for treatment is also described.

Abstract: The current disclosure, in one embodiment, includes a polysaccharide conjugate. This conjugate has a polysaccharide and at least one monomeric amino acid having an O-group covalently bound to the polysaccharide. The conjugate also has at least one metal conjugated by the O-group of the amino acid. According to another embodiment, the disclosure provides a method of synthesizing a polysaccharide conjugate by covalently bonding a monomeric amino acid having an O-group to a polysaccharide and by conjugating a metal to the O-group to form a polysaccharide conjugate. According to a third embodiment, the disclosure relates to a method of killing a cancer cell by administering to the cell an effective amount of a polysaccharide conjugate. This conjugate has a polysaccharide and at least one monomeric amino acid having an O-group covalently bound to the polysaccharide. The conjugate also has at least one metal conjugated by the O-group of the amino acid.

Abstract: This invention discloses chemically modified polyaminosaccharides, in particular chemically modified chitosans, in the molecular structure of which a predetermined proportion of the amino functional groups is sulfonated by the hydrocarbyl sultone compound via a covalent bond. Such chemically modified polyaminosaccharides may be produced by a process of sulfonating an un-modified polyaminosaccharide having amino functional groups by a hydrocarbyl sultone compound in the presence of an organic solvent under a suitable temperature. Chemically modified chitosans of this invention may be used in a variety of applications, including wound healing.

Abstract: The invention include glycopeptides having a glycoside and a peptide covalently bound through an amide bond. The glycopeptides may also include a diagnostic or therapeutic agent bound to the glycopeptide. A metal, such as a radionuclide, may also be chelated to the glycopeptide. Specific embodiments of the invention relate to glycopeptides made of chitosan covalently bound to a poly(amino acid) such as poly(glutamic acid) or poly(aspartic acid). Diagnostic agents conjugated to the glycopeptide may facilitate imaging. Specific therapeutic agents that may be conjugated to the glycopeptide include anticancer drugs, rheumatoid arthritis drugs, anticoagulants, anti-angiogenesis drugs, apoptosis drugs, osteoporosis drugs, steroids, and anti-inflammatory drugs. Some agents, such as radionuclides, may have both diagnostic and therapeutic effects.

Abstract: The current disclosure, in one embodiment, includes a polysaccharide conjugate. This conjugate has a polysaccharide and at least one monomeric amino acid having an O-group covalently bound to the polysaccharide. The conjugate also has at least one metal conjugated by the O-group of the amino acid. According to another embodiment, the disclosure provides a method of synthesizing a polysaccharide conjugate by covalently bonding a monomeric amino acid having an O-group to a polysaccharide and by conjugating a metal to the O-group to form a polysaccharide conjugate. According to a third embodiment, the disclosure relates to a method of killing a cancer cell by administering to the cell an effective amount of a polysaccharide conjugate. This conjugate has a polysaccharide and at least one monomeric amino acid having an O-group covalently bound to the polysaccharide. The conjugate also has at least one metal conjugated by the O-group of the amino acid.

Abstract: The invention include glycopeptides having a glycoside and a peptide covalently bound through an amide bond. The glycopeptides may also include a diagnostic or therapeutic agent bound to the glycopeptide. A metal, such as a radionuclide, may also be chelated to the glycopeptide. Specific embodiments of the invention relate to glycopeptides made of chitosan covalently bound to a poly(amino acid) such as poly(glutamic acid) or poly(aspartic acid). Diagnostic agents conjugated to the glycopeptide may facilitate imaging. Specific therapeutic agents that may be conjugated to the glycopeptide include anticancer drugs, rheumatoid arthritis drugs, anticoagulants, anti-angiogenesis drugs, apoptosis drugs, osteoporosis drugs, steroids, and anti-inflammatory drugs. Some agents, such as radionuclides, may have both diagnostic and therapeutic effects.

Abstract: This invention discloses chemically modified polyaminosaccharides, in particular chemically modified chitosans, in the molecular structure of which a predetermined proportion of the amino functional groups is sulfonated by the hydrocarbyl sultone compound via a covalent bond. Such chemically modified polyaminosaccharides may be produced by a process of sulfonating an un-modified polyaminosaccharide having amino functional groups by a hydrocarbyl sultone compound in the presence of an organic solvent under a suitable temperature. Chemically modified chitosans of this invention may be used in a variety of applications, including wound healing.

Abstract: Alkylsulfonated polyaminosaccharides, such as alkylsulfonated chitosan, having a sultone substituent covalently bonded to the amino group and a known size and degree of substitution may be produced by methods of the invention. Such methods may include heating of the polyaminosaccharide in a polar solvent, such as alcohol, ether, or alcoholether to reflux, then adding an alkyl sultone. Alkylsulfonated polyaminosaccharides of the present invention may be used in a wide variety of applications. Alkylsulfonated chitosan is particularly useful in wound healing.

Abstract: The present invention pertains to a process for preparing clusters of infusible, inherently tacky, elastomeric, solvent-insoluble, solvent-dispersible polymeric microparticles by aqueous emulsion polymerization. The invention also pertains to an adhesive comprising the polymeric microparticles and to a repeatedly reusable pressure sensitive sheet material having the elastomeric microparticles coated thereon.

Abstract: The present invention pertains to a process for preparing clusters of infusible, inherently tacky, elastomeric, solvent-insoluble, solvent-dispersible polymeric microparticles by aqueous emulsion polymerization. The invention also pertains to an adhesive comprising the polymeric microparticles and to a repeatedly reusable pressure sensitive sheet material having the elastomeric microparticles coated thereon.